Compare CUE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | LYEL |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 195.8M |
| IPO Year | 2017 | 2021 |
| Metric | CUE | LYEL |
|---|---|---|
| Price | $4.59 | $13.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $68.67 | $37.63 |
| AVG Volume (30 Days) | ★ 552.6K | 208.9K |
| Earning Date | 11-16-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $7.20 |
| 52 Week High | $45.50 | $45.00 |
| Indicator | CUE | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 53.58 |
| Support Level | $0.22 | $12.25 |
| Resistance Level | $33.95 | $14.97 |
| Average True Range (ATR) | 2.75 | 1.66 |
| MACD | -1.47 | -0.12 |
| Stochastic Oscillator | 8.18 | 41.29 |
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.